Trial reportThe Lancet. Infectious diseases2022
Efficacy of RTS,S/AS01
Trial report in The Lancet. Infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Efficacy and safety of RTS, S and R21 malaria vaccines in children under five in Africa: a systematic review and meta-analysis of randomized controlled trials.Malaria journal · 2026Pooled it
- Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis.Systematic reviews · 2025Pooled it
- Determinants of Malaria Vaccine Acceptance: A Systematic Review and Meta-Analysis of Awareness, Acceptance, Hesitancy, and Willingness to Pay.Immunity, inflammation and disease · 2025Pooled it
- Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet (London, England) · 2026Trial
- Sustained efficacy of the RTS,S/AS01The Lancet. Global health · 2025Trial
- Genotypic analysis of RTS,S/AS01The Lancet. Infectious diseases · 2024Trial
- Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine.The Journal of infectious diseases · 2024Trial
- Structural and mechanistic insights into the inhibition of Plasmodium falciparum MDR1.Nature communications · 2026Article
- Community health volunteers improve access to malaria case management in Siaya County, Kenya.Malaria journal · 2026Article
- B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.Frontiers in immunology · 2026Article
- A viral-vectored multipathogen vaccine platform based on replication-competent vaccinia virus and adeno-associated virus.Frontiers in immunology · 2026Article
- Malaria vaccines: Current developments and immunological insights.New microbes and new infections · 2025Article
- Global medium-term research priority setting for seasonal malaria chemoprevention: results from an eDelphi study.BMJ global health · 2025Article
- Generalized nonparametric temporal modeling of recurrent events with application to a malaria vaccine trial.Biometrics · 2025Article
- Emerging Role of Splenic Macrophage in Malaria Pathogenesis and Immunity.Immunity, inflammation and disease · 2025Review
- Genetic polymorphism of msp2 in Plasmodium falciparum isolates among asymptomatic malaria infections from two ecological settings in Cameroon.Malaria journal · 2025Article
- Controlled Human Infection Studies Accelerate Vaccine Development.The Journal of infectious diseases · 2025Article
- Mathematical modeling of malaria vaccination with seasonality and immune feedback.PLoS computational biology · 2025Article
- Where is the hard-to-reach population? Spatial analysis from a cross-sectional study on the access to bed net and malaria vaccine in the Lake Victoria Region, Kenya.Malaria journal · 2025Article
- Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
27 authors at 6 institutions in 4 countries.
Funding
Abstract
backgroundControlled infection studies in malaria-naive adults suggest increased vaccine efficacy for fractional-dose versus full-dose regimens of RTS,S/AS01. We report first results of an ongoing trial assessing different fractional-dose regimens in children, in natural exposure settings.
methodsThis open-label, phase 2b, randomised controlled trial is conducted at the Malaria Research Center, Agogo, Ashanti Region (Ghana), and the Kenya Medical Research Institute and the US Centers for Disease Control and Prevention site in Siaya County (Kenya). We enrolled children aged 5-17 months without serious acute or chronic illness who had previously received three doses of diphtheria, tetanus, pertussis, and hepatitis B vaccine and at least three doses of oral polio vaccine. Children were randomly assigned (1:1:1:1:1) using a web-based randomisation system with a minimisation procedure accounting for centre to receive rabies control vaccine (M012 schedule) or two full doses of RTS,S/AS01
findingsBetween Sept 28, 2017, and Sept 25, 2018, 2157 children were enrolled, of whom 1609 were randomly assigned to a treatment group (322 to each RTS,S/AS01
interpretationThe Fx012-14 regimen was not superior to the standard regimen over 12 months after dose three. All RTS,S/AS01
fundingGlaxoSmithKline Biologicals; PATH's Malaria Vaccine Initiative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.